Compare Canadian Natural Resources Ltd. (CNQ) vs Cassava Sciences Inc (FLNA) Price & Performance

CNQ trades at $43.05, up 2.97% today, with a bullish technical signal supported by moving averages and ADX. The stock shows strong fundamentals with a P/E of 11.8, net income margin of 24.5%, and consistent earnings beats in recent quarters. Recent news highlights its robust asset base and operational efficiency amid volatile oil markets. Cash flow remains positive, with 2025 net cash flow at $542 million.

Outlook is positive with analyst consensus strongly favoring Buy (75%), driven by valuation appeal and shareholder returns via dividends and buybacks. Key risks include oil price volatility and rising debt-to-asset ratio, which increased to 22.04% in 2024. The stock's proximity to its 52-week high suggests cautious optimism, but fundamentals support long-term growth potential.

FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.

Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.